245 related articles for article (PubMed ID: 25677978)
21. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
22. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
23. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
24. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
25. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
26. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
[TBL] [Abstract][Full Text] [Related]
27. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases.
Bussaglia E; del Rio E; Matias-Guiu X; Prat J
Hum Pathol; 2000 Mar; 31(3):312-7. PubMed ID: 10746673
[TBL] [Abstract][Full Text] [Related]
28. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
[TBL] [Abstract][Full Text] [Related]
29. Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.
Espinosa I; D'Angelo E; Palacios J; Prat J
Am J Surg Pathol; 2016 Jul; 40(7):972-81. PubMed ID: 26975040
[TBL] [Abstract][Full Text] [Related]
30. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
31. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
32. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract][Full Text] [Related]
33. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
34. Cervical cytology in serous and endometrioid endometrial cancer.
Roelofsen T; Geels YP; Pijnenborg JM; van Ham MA; Zomer SF; van Tilburg JM; Snijders MP; Siebers AG; Bulten J; Massuger LF
Int J Gynecol Pathol; 2013 Jul; 32(4):390-8. PubMed ID: 23722512
[TBL] [Abstract][Full Text] [Related]
35. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
36. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
[TBL] [Abstract][Full Text] [Related]
37. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome.
Wadee R; Grayson W
Ann Diagn Pathol; 2019 Apr; 39():92-104. PubMed ID: 30798077
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
39. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]